Insider Buying: Bluejay Diagnostics (NASDAQ:BJDX) Director Acquires $25,000.00 in Stock

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Director Fred Zeidman bought 12,500 shares of Bluejay Diagnostics stock in a transaction dated Saturday, March 14th. The stock was purchased at an average price of $2.00 per share, with a total value of $25,000.00. Following the completion of the purchase, the director owned 12,500 shares in the company, valued at $25,000. This trade represents a ? increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Bluejay Diagnostics Price Performance

Shares of BJDX opened at $1.78 on Thursday. The stock has a 50-day moving average of $1.89 and a 200-day moving average of $3.09. The company has a market cap of $1.83 million, a PE ratio of -0.15 and a beta of 0.72. Bluejay Diagnostics, Inc. has a one year low of $1.62 and a one year high of $16.68.

Bluejay Diagnostics (NASDAQ:BJDX) last issued its earnings results on Thursday, May 7th. The company reported ($1.95) EPS for the quarter.

Institutional Trading of Bluejay Diagnostics

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new stake in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned approximately 9.15% of Bluejay Diagnostics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 18.47% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research note on Friday, March 27th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.